Immobilized Human IL-18, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for IL-18BP hFc Chimera, Human, hFc Tag with the EC50 of 16.9 ng/ml determined by ELISA.
IL-18BP hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
IL-18BP hFc Chimera, Human, hFc Tag captured on Protein A chip, can bind Human IL-18 with an affinity constant of 0.04nM as determined in a SPR assay (Biacore T200).
The purity of IL-18BP hFc Chimera, Human is greater than 90% as determined by SEC-HPLC.
IL-18BP hFc Chimera, Human
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
| Z05453 | |
|
|
|
| ¥31,712.00 | |
|
|
|
|
|
|
| Ask us a question | |
